FREEDOM trial 3,591 postmenop. women Rx w/ denosumab vs PBO x3 years - No difference in dental procedures (~45%), adjudicated osteonecrosis of jaw (13 cases) - risk was 0.68% vs. 0.05% w/ and withour invasive oral procedures. https://t.co/dxWuzEjUnk